Journal of Histochemistry and Cytochemistry
  Search:   
    >> Advanced Search

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahmed, N.
Right arrow Articles by Baker, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahmed, N.
Right arrow Articles by Baker, M. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Histochemistry and Cytochemistry, Vol. 50, 1371-1380, October 2002, Copyright © 2002, The Histochemical Society, Inc.

ARTICLE

{alpha}vß6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer

Nuzhat Ahmeda,b, Clyde Rileya, Gregory E. Ricea,b, Michael A. Quinna,b, and Mark S. Bakera
a Gynaecological Cancer Research Centre, The University of Melbourne and Royal Women's Hospital, Carlton, Victoria, Australia
b Department of Obstetrics and Gynaecology, The University of Melbourne and Royal Women's Hospital, Carlton, Victoria, Australia

Correspondence to: Nuzhat Ahmed, Gynaecological Cancer Research Centre, Royal Women's Hospital, 132 Grattan Street, Carlton, Victoria 3053, Australia. E-mail: nuzhata@unimelb.edu.au

The mechanism(s) responsible for the progression of non-metastatic or borderline ovarian cancer to invasive Grade I/III ovarian cancer is still unknown. An epithelium-restricted integrin, {alpha}vß6, is present in malignant epithelia but not in normal epithelia. We studied the relative expression and distribution of {alpha}vß6 integrin in early and late-stage invasive (Grade I and Grade III) and non-invasive (benign and borderline) ovarian tumors of serous, mucinous, endometrioid, and clear-cell carcinoma subtypes, to assess its potential as a marker for epithelial ovarian cancer progression. Sixty-six specimens, including eight normal, 13 benign, 14 borderline, 13 Grade I, and 18 Grade III tumors were evaluated by immunohistochemistry (IHC) using a monoclonal antibody (MAb) against {alpha}vß6 integrin. Normal ovarian surface epithelium was negative for {alpha}vß6 integrin expression. All 45 carcinomas studied were positive, and the staining intensity significantly correlated with the grade of the tumor. The Grade III carcinomas of all types showed strong staining intensity. Only mucinous benign tissues were positive, and no reactivity was observed in benign serous neoplasms. On the basis of these observations, we hypothesize that the expression of {alpha}vß6 integrin is associated with epithelial ovarian cancer and that a gradual increase in the expression of the molecule may be a correlative index of the progression of this disease.

(J Histochem Cytochem 50:1371–1379, 2002)

Key Words: {alpha}vß6 integrin, epithelial cells, ovarian cancer, metastasis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
L. Coughlan, S. Vallath, A. Saha, M. Flak, I. A. McNeish, G. Vassaux, J. F. Marshall, I. R. Hart, and G. J. Thomas
In Vivo Retargeting of Adenovirus Type 5 to {alpha}v{beta}6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery
J. Virol., July 1, 2009; 83(13): 6416 - 6428.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
B. Chen, E. Goodman, Z. Lu, A. Bandyopadhyay, C. Magraw, T. He, and S. Raghavan
Function of {beta}1 Integrin in Oral Epithelia and Tooth Bud Morphogenesis
Journal of Dental Research, June 1, 2009; 88(6): 539 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Li, M. J. McGuire, M. Lin, Y.-H. Liu, T. Oyama, X. Sun, and K. C. Brown
Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications
Mol. Cancer Ther., May 1, 2009; 8(5): 1239 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. Elayadi, K. N. Samli, L. Prudkin, Y.-H. Liu, A. Bian, X.-J. Xie, I. I. Wistuba, J. A. Roth, M. J. McGuire, and K. C. Brown
A Peptide Selected by Biopanning Identifies the Integrin {alpha}v{beta}6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer
Cancer Res., June 15, 2007; 67(12): 5889 - 5895.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Nystrom, D. McCulloch, P. H. Weinreb, S. M. Violette, P. M. Speight, J. F. Marshall, I. R. Hart, and G. J. Thomas
Cyclooxygenase-2 Inhibition Suppresses {alpha}v{beta}6 Integrin-Dependent Oral Squamous Carcinoma Invasion.
Cancer Res., November 15, 2006; 66(22): 10833 - 10842.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. R. Morgan, G. J. Thomas, A. Russell, I. R. Hart, and J. F. Marshall
The Integrin Cytoplasmic-tail Motif EKQKVDLSTDC Is Sufficient to Promote Tumor Cell Invasion Mediated by Matrix Metalloproteinase (MMP)-2 or MMP-9
J. Biol. Chem., June 18, 2004; 279(25): 26533 - 26539.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
N. Ahmed, C. Riley, K. Oliva, G. Barker, M. A. Quinn, and G. E. Rice
Expression and localization of {alpha}v{beta}6 integrin in extraplacental fetal membranes: possible role in human parturition
Mol. Hum. Reprod., March 1, 2004; 10(3): 173 - 179.
[Abstract] [Full Text] [PDF]



Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact
The Journal of Histochemistry & Cytochemistry is owned, published, and licensed by The Histochemical Society © 2002

 
MARC Travel Awards to IHC&M 2010